<DOC>
	<DOC>NCT02952534</DOC>
	<brief_summary>The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib.</brief_summary>
	<brief_title>A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Rucaparib</mesh_term>
	<criteria>Be 18 years old at the time the informed consent form is signed Have a histologically or cytologically confirmed adenocarcinoma or poorly differentiated carcinoma of the prostate Be surgically or medically castrated, with serum testosterone levels of â‰¤ 50 ng/dL (1.73 nM) Experienced disease progression after having received at least 1 but no more than 2 prior nextgeneration androgen receptortargeted therapies, and 1 prior taxanebased chemotherapy, for castrationresistant disease Have a deleterious mutation in BRCA1/2 or ATM, or molecular evidence of other homologous recombination deficiency Active second malignancy, with the exception of curatively treated nonmelanoma skin cancer, carcinoma in situ, or superficial bladder cancer Prior treatment with any PARP inhibitor, mitoxantrone, cyclophosphamide or any platinumbased chemotherapy Symptomatic and/or untreated central nervous system metastases Preexisting duodenal stent and/or any gastrointestinal disorder or defect that would, in the opinion of the investigator, interfere with absorption of rucaparib</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>CRPC</keyword>
	<keyword>PARP inhibitor</keyword>
	<keyword>PARPi</keyword>
	<keyword>BRCA</keyword>
	<keyword>ATM</keyword>
	<keyword>HRD</keyword>
	<keyword>TRITON</keyword>
	<keyword>homologous recombination</keyword>
	<keyword>DNA repair</keyword>
	<keyword>DNA defect</keyword>
	<keyword>DNA anomaly</keyword>
	<keyword>BARD1</keyword>
	<keyword>BRIP1</keyword>
	<keyword>CDK12</keyword>
	<keyword>CHEK2</keyword>
	<keyword>FANCA</keyword>
	<keyword>NBN</keyword>
	<keyword>PALB2</keyword>
	<keyword>RAD51</keyword>
	<keyword>RAD51B</keyword>
	<keyword>RAD51C</keyword>
	<keyword>RAD51D</keyword>
	<keyword>RAD54L</keyword>
	<keyword>germline</keyword>
	<keyword>somatic</keyword>
</DOC>